Loading organizations...
Loading organizations...
Key people at Monograph Capital.
Monograph Capital was founded in 2021 by Charles Conn (Co-founder).
We are Monograph Capital. We find and fund innovative life sciences companies, aiming to help translate promising science into potential, life-changing treatments for patients around the world.
Monograph Capital was founded in 2021 by Charles Conn (Co-founder).
Monograph Capital is a venture capital firm specializing in the life sciences sector, with a mission to find and fund groundbreaking companies that transform promising scientific discoveries into life-changing medical treatments globally. The firm invests across therapeutics, diagnostics, and technology-enabled healthcare services, supporting early-stage and growth-stage companies with capital, strategic guidance, and deep industry expertise. Monograph leverages its strong network within the pharmaceutical industry and its team’s medical and operational knowledge to accelerate innovation and improve health outcomes worldwide[1][2][3].
Founded with offices in London and San Francisco, Monograph Capital was established by partners including Charles Conn and Bonnie van Wilgenburg, among others, who bring extensive experience in life sciences investment and operations. The firm evolved to focus on bridging resources and expertise to scale companies that change the practice of medicine. Its transatlantic team combines decades-long pharma relationships, medical insight, and operating experience to identify breakthrough science and build successful companies across borders[3][5][6].
Monograph Capital rides the wave of rapid advancements in biotechnology, gene therapy, AI-powered healthcare platforms, and precision medicine. The timing is crucial as breakthroughs in biomedical technologies and regulatory environments create fertile ground for transformative therapies. By investing in cutting-edge science and enabling startups to scale, Monograph influences the broader ecosystem by accelerating the translation of research into clinical and commercial success, ultimately shaping future standards of care[1][2][4].
Looking ahead, Monograph Capital is poised to deepen its impact by continuing to back pioneering life sciences ventures that address unmet medical needs. Trends such as AI integration in drug development, gene editing, and personalized medicine will likely shape their investment focus. Their influence is expected to grow as they leverage their unique blend of capital, expertise, and network to help startups navigate complex development pathways and bring novel therapies to market, reinforcing their role as a key catalyst in the life sciences innovation landscape[3][4][6].
Key people at Monograph Capital.
